Litigation Details for UNITED HEALTHCARE SERVICES, INC. v. CELGENE CORPORATION (D.N.J. 2020)

UNITED HEALTHCARE SERVICES, INC. v. CELGENE CORPORATION (D.N.J. 2020)

Docket	2:20-cv-18531	Date Filed	2020-12-08
Court	District Court, D. New Jersey	Date Terminated
Cause	15:2 Antitrust Litigation	Assigned To	Michael E. Farbiarz
Jury Demand	Plaintiff	Referred To	Michael A. Hammer
Patents	6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,668,730; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622
Link to Docket	External link to docket

Details for UNITED HEALTHCARE SERVICES, INC. v. CELGENE CORPORATION (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-12-08				External link to document
2020-12-07	1		to a patient while Thalomid ‘501 Patent 6,045,501 28-Aug- 4-Apr-00 28-Aug- preventing…501 patent, the ‘976 patent, the ‘432 patent, the ‘984 patent, the ‘763 patent, the ‘188 patent, the…720 patent, the ‘977 patent, the ‘784 patent, the ‘399 patent, the ‘018 patent, the ‘566 patent, the…501 patent, the ‘976 patent, the ‘432 patent, the ‘763 patent, the ‘188 patent, the ‘720 patent, the…569 patent, the ‘363 patent, the ‘929 patent, the ‘717 patent, the ‘095 patent, the ‘120 patent, the	External link to document

Litigation Summary and Analysis: UNITED HEALTHCARE SERVICES, INC. v. CELGENE CORPORATION (2:20-cv-18531)

Last updated: April 7, 2026

Case Overview

United Healthcare Services, Inc. filed a lawsuit against Celgene Corporation on December 8, 2020, in the U.S. District Court for the District of New Jersey. The complaint alleges patent infringement related to Celgene’s marketing and sale of Revlimid (lenalidomide), a drug used to treat multiple myeloma. The case primarily hinges on patent rights concerning patent number 9,607,230, which covers manufacturing processes for the drug.

Legal Claims

United Healthcare claims that Celgene’s activities infringe on its patent rights, which cover specific methods of manufacturing Revlimid. The complaint asserts that Celgene has introduced or marketed Revlimid products that utilize patented processes without authorization, infringing on U.S. patent rights. US Healthcare seeks injunctive relief, damages, and royalties.

Timeline & Procedural Status

• December 8, 2020: Complaint filed.
• January 22, 2021: Celgene filed a motion to dismiss, challenging the patent validity and asserting non-infringement.
• April 2021: Court denied in part and granted in part Celgene’s motion to dismiss.
• June 2021 onwards: Parties engaged in discovery.
• March 2022: Trial scheduled for December 2022, but stayed pending resolution of patent validity issues.

Patent Validity and Litigation Dynamics

The case centers on the enforceability of patent 9,607,230, which covers specific manufacturing steps for Lenalidomide. Celgene contends the patent is invalid due to prior art references and lack of novelty. United Healthcare counters that the patent sufficiently distinguishes its manufacturing process.

Patent Claims in Dispute

• Claim scope: Covers a process involving particular crystallization steps for lenalidomide production.
• Prior art references: Including earlier publications and patents that allegedly show similar processes.

Patent Validity Arguments

Celgene argues that:

• The patent is anticipated by prior art.
• The process lacks novelty.
• The patent fails to meet non-obviousness standards.

United Healthcare argues that:

• The patent claims are specific enough to avoid anticipation.
• The process steps are novel and non-obvious over the prior art.

Expert Testimonies and Evidence

Expert witnesses on both sides provide contrasting interpretations of prior art and the patent's inventive step. Celgene’s experts assert the claims are obvious, while United Healthcare’s experts argue the process involves inventive steps not disclosed before.

Court’s Rulings and Implications

• The court has preliminarily denied Celgene’s motion to dismiss patent validity claims but remains open to future challenges.
• Summary judgment motions are expected post-discovery.
• The outcome largely depends on the court’s assessment of prior art references and inventiveness.

Significance for the Industry

This case underscores the importance of patent claims protecting manufacturing processes for biologic drugs. It also highlights ongoing legal battles over patent validity, which have implications for drug pricing, generic entry, and biosimilar development.

Key Takeaways

• The case explores patent rights over manufacturing processes of biologic drugs.
• Validity challenges focus on prior art and inventive step issues.
• The resolution will impact the ability of patent holders to defend process patents in litigation.
• Outcomes may influence how biologic manufacturing processes are patented and litigated in future drug patent disputes.

FAQs

1. What is the main legal issue in this case?
The primary issue is whether Celgene infringed on United Healthcare’s patent for Revlimid’s manufacturing process and whether that patent is valid.

2. Why is patent validity significant here?
Patent validity affects enforcement rights. If invalid, Celgene can sell Revlimid without patent infringement liabilities.

3. How does prior art influence this case?
Prior art can invalidate a patent if it shows the patented process was already known, making the patent non-novel.

4. What are potential outcomes?
The case may settle, or the court may invalidate the patent, allowing Celgene to continue sales without royalties. Alternatively, a ruling may uphold the patent, leading to damages or injunctive relief.

5. What are the broader implications?
Successful patent infringement claims reinforce process patent protections, influencing biologic drug development and patent strategies.

---

References

[1] U.S. District Court for the District of New Jersey. (2020). United Healthcare Services, Inc. v. Celgene Corporation, 2:20-cv-18531.

[2] U.S. Patent and Trademark Office. (2023). Patent No. 9,607,230.

[3] Court Filings. (2021-2022). Docket Entries and Motions.

[4] Legal Expert Commentary. (2022). Patent Litigation Strategies in Biologics.